Hansa Biopharma (OM:HNSA) Stock Faces Deeper Q2 Loss Challenging Growth Optimism

Hansa Biopharma (OM:HNSA) has released its Q2 2026 results, reporting revenue of 48.1 million SEK, a basic EPS loss of 2.56 SEK, and net income excluding extra items showing a loss of 260.5 million SEK. These figures provide a snapshot of how the business is balancing growth and profitability. Over recent quarters, the company has reported revenue in a range between 30.8 million SEK and 75.99 million SEK, while quarterly basic EPS losses have ranged from 0.57 SEK to 2.56 SEK. This highlights a business that is increasing its revenue while still incurring substantial losses. For investors, this quarter can be seen as a gauge of how much revenue momentum may help to counter margin pressure and ongoing losses.

See our full analysis for Hansa Biopharma.

With the latest figures available, the next step is to assess how these results compare with the widely followed views on Hansa Biopharma's growth potential and risk profile, and where those perspectives may need to be revised.

See what the community is saying about Hansa Biopharma

Losses Deepen With Q2 Net Income Of SEK 260.5 Million

• Hansa Biopharma reported a Q2 2026 net income loss excluding extra items of SEK 260.5 million, compared with losses between SEK 148.3 million and SEK 196.3 million in each of the previous three quarters.
• Bears argue that persistent losses and reliance on future approvals keep the business on fragile footing, and the trailing 12 month loss of SEK 773.2 million together with forecasts for continued unprofitability over the next three years align with that concern.
  • The loss trend over the last five years has moved roughly 4.6% deeper per year, and recent quarterly EPS losses between SEK 0.57 and SEK 2.56 per share underline how far the company remains from breakeven.
  • Analysts expecting revenue growth to eventually reach SEK 906.4 million with SEK 185.3 million in earnings in one of the bearish scenarios are implicitly assuming a very large swing from the current SEK 773.2 million trailing 12 month loss, which highlights how much needs to change for that view to play out.

For a closer look at why some investors think these results still leave room for disappointment, and how much depends on future trial outcomes, check out the bear case on Hansa Biopharma 🐻 Hansa Biopharma Bear Case.

Fast Revenue Growth Versus SEK 773.2 Million TTM Loss

• On a trailing 12 month basis Hansa Biopharma generated SEK 189.5 million of revenue, while recording a net income loss excluding extra items of SEK 773.2 million and a trailing basic EPS loss of SEK 7.94 per share.
• Bullish investors highlight strong top line potential, pointing to revenue forecasts of about 42.2% growth per year and scenarios where revenue could reach SEK 2.1 billion with SEK 420.0 million of earnings, yet the current ratio of SEK 773.2 million of losses to SEK 189.5 million of revenue shows how far the income statement would need to shift to meet that view.
  • The bullish case requires margins to move from very negative levels today toward sector averages near 20%, a sharp contrast with the present situation where quarterly losses such as SEK 260.5 million in Q2 2026 absorb more than the entire quarter’s SEK 48.1 million of revenue.
  • Even with the current share price at SEK 32.08 and analyst price targets such as SEK 73.00 being discussed, the gap between current losses and those bullish earnings assumptions means investors need to judge whether revenue growth can realistically offset the present cost base.

Supporters of the growth story argue that these heavy losses could eventually set up operating leverage, and you can see how that optimistic scenario is framed in the full bull case on Hansa Biopharma 🐂 Hansa Biopharma Bull Case.

Balance Sheet Pressure And Valuation Tension For Hansa Biopharma

• The company is running with negative shareholders’ equity and less than one year of cash runway, while trading on a P/S of 17.2x that sits below direct peers at 20.7x but above the Swedish biotech industry average of 9.7x.
• Consensus narrative focuses on this mix of growth and financial strain, arguing that strong revenue prospects can justify the current valuation, yet the combination of negative equity, cash runway under one year and past shareholder dilution shows why funding risk remains central to the story.
  • Recent dilution, together with expectations that shares outstanding may grow by about 7% per year in some analyst scenarios, means any future earnings improvement would be shared across a larger base, which matters if investors are comparing the current SEK 32.08 share price with targets like SEK 73.00.
  • The fact that the P/S sits between peer and broader industry levels suggests the market is already weighing the forecast 42.2% annual revenue growth against these balance sheet pressures, rather than treating Hansa Biopharma as either a pure bargain or purely expensive.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Hansa Biopharma on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If the mix of cautious and optimistic views on Hansa Biopharma leaves you uncertain, review the figures, weigh the trade offs, and then assess the 1 key reward and 4 important warning signs.

See What Else Is Out There

Hansa Biopharma is carrying heavy and persistent losses, negative shareholders’ equity, and a short cash runway, all against a valuation that already prices in ambitious expectations.

If that mix of funding risk and deep losses makes you cautious, it is worth comparing with companies screened for resilient finances using the 293 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com